A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Conditions
Advanced Solid Tumors That Are MTAP Deficient
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, San Francisco, California, United States
Research Site, West Hollywood, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Baltimore, Maryland, United States
Research Site, Portland, Oregon, United States
Research Site, Pittsburgh, Pennsylvania, United States
Research Site, Providence, Rhode Island, United States
Research Site, Fairfax, Virginia, United States
Research Site, Melbourne, Australia
Research Site, Beijing, China
Research Site, Chengdu, China
Research Site, Shanghai, China
Research Site, Villejuif, France
Research Site, Chūōku, Japan
Research Site, Kashiwa, Japan
Research Site, Amsterdam, Netherlands
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Barcelona, Spain
Research Site, Madrid, Spain